Using Topical Difluprednate to Treat Noninfectious Uveitic C
Cystoid macular edema (CME) is a common cause of visual loss in patients with uveitis, accounting for 42 to 44 percent of visual impairment or legal blindness.[i] Yet evidence-based treatment strategies for CME are lacking, with most uveitis experts relying on personal experience for treatment decisions.

Common treatments include systemic, periocular or intraocular steroids with innovations in delivery routes and steroid sparing agents showing reduced side effects, improved durability and, in some cases, increased efficacy. Also, local delivery in the forms of intravitreal injection or slow-release corticosteroid implants can be effective, though there are significant side effects including cataract formation, elevated risk of glaucoma, endophthamitis and retinal detachment....